AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18021337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 66
Study 18021337 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 66
Study 18021337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 66
Study 15193818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Simvastatin 20 mg daily
Number of subjects: 63
Study 15193818 — intervention group
Group type: COMPARATOR
Intervention: Diet (Control)
Number of subjects: 63
Study 11463131 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing dextrose tablets
Number of subjects: 0
Study 11463131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9874905 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced standard methadone maintenance intervention (E‐STD)
Number of subjects: 307
Study 9874905 — intervention group
Group type: COMPARATOR
Intervention: High‐intensity, socially demanding day treatment program (DTP)
Number of subjects: 307
Study 7978377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm preparation using immunobeads
Number of subjects: 6
Study 2926575 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone-hydrochlorothiazide (Aldactazide) at 3 mg/kg/day for 6 to 8 days (n = 12)
Number of subjects: 21
Study 2926575 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 9)
Number of subjects: 21
Study 4593554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (25 to 75 mcg twice daily)
Number of subjects: 100
Study 4593554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31397866 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (rotator cuff surgery followed by approximately 4 months of postoperative rehabilitation)
Number of subjects: 700
Study 31397866 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (approximately 3‐month standardized physical therapy program)
Number of subjects: 700
Study 28244415 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid honey (10 mL, 4 times a day)
Number of subjects: 163
Study 28244415 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge honey (10 mL, 4 times a day)
Number of subjects: 163
Study 28244415 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 163
Study 25529033 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU)
Number of subjects: 41
Study 25529033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of IGU and methotrexate
Number of subjects: 41
Study 22812912 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 1: acid-etching (dentin) + silica coating (composite) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Number of subjects: 72
Study 22812912 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2: silica coating (composite) + acid-etching (dentin) + silanization (composite) + primer (dentin) + bonding agent (dentin + composite)
Number of subjects: 72
Study 22812912 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 3: acid-etching (dentin) + primer (dentin) + silanization (composite) + bonding agent (dentin + composite)
Number of subjects: 72
Study 21166480 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 300 mg/day
Number of subjects: 104
Study 21166480 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide 400 mg/day
Number of subjects: 104
Study 21166480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 21166480 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (300 and 400 mg/day)
Number of subjects: 104
Study 21166480 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 104
Study 18377143 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic taper intervention with self-help treatment for insomnia
Number of subjects: 0
Study 18377143 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic taper intervention without self-help treatment for insomnia
Number of subjects: 0
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 1)
Number of subjects: 31
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (cohort 2)
Number of subjects: 31
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied once daily for 2 weeks (all cohorts)
Number of subjects: 31
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks (all cohorts)
Number of subjects: 31
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied once daily for 2 weeks
Number of subjects: 31
Study 17178982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluocinonide cream applied twice daily for 2 weeks
Number of subjects: 31
Study 15006251 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 0
Study 15006251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nasopharyngeal culture for S. pneumoniae in NT‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nasopharyngeal culture for S. pneumoniae in NR‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for S. pneumoniae in NR‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for S. pneumoniae in NT‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NT‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative nasopharyngeal culture for antibiotic-resistant S. pneumoniae in NR‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal colonization with penicillin-nonsusceptible S. pneumoniae in NR‐AOM
Number of subjects: 579
Study 10783018 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal colonization with penicillin-nonsusceptible S. pneumoniae in NT‐AOM
Number of subjects: 579
Study 8653625 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium eye drops 0.1% (Naclof)
Number of subjects: 60
Study 8653625 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone eye drops 0.1% (Dexamethasone oph.)
Number of subjects: 60
Study 1458764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole (20mg)
Number of subjects: 14
Study 1458764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole (40mg)
Number of subjects: 14
Study 1458764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral omeprazole
Number of subjects: 14
Study 1458764 — intervention group
Group type: COMPARATOR
Intervention: Comparison with young individuals
Number of subjects: 14
Study 6327543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 600 mg intramuscularly daily for 12 days
Number of subjects: 32
Study 6327543 — intervention group
Group type: COMPARATOR
Intervention: Rifampin 600 mg daily for 21 days
Number of subjects: 32
Study 6327543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sodium stibogluconate and rifampin
Number of subjects: 32
Study 30772898 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral indications of assent, level of intimacy between the couple, and age of respondent
Number of subjects: 389
Study 30772898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition and relationship levels
Number of subjects: 389
Study 29804728 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to frontline therapy
Number of subjects: 305
Study 29804728 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease stabilization
Number of subjects: 305
Study 27902612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstyletted endotracheal tube with exaggerated curvature
Number of subjects: 140
Study 27902612 — intervention group
Group type: COMPARATOR
Intervention: Styletted endotracheal tube
Number of subjects: 140
Study 24812022 — intervention group
Group type: COMPARATOR
Intervention: Basic Internet (BI)
Number of subjects: 2005
Study 24812022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet (EI)
Number of subjects: 2005
Study 24812022 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Internet plus telephone counseling (EI+P)
Number of subjects: 2005
Study 24812022 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-assigned treatments (pharmacotherapy, behavioral, alternative, non-study Internet)
Number of subjects: 2005
Study 22445846 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 24
Study 22445846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20482243 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro pen
Number of subjects: 367
Study 19018255 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual support
Number of subjects: 481
Study 19018255 — intervention group
Group type: EXPERIMENTAL
Intervention: Group rehabilitation
Number of subjects: 481
Study 19018255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of individual support and group rehabilitation
Number of subjects: 481
Study 19018255 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 481
Study 15282351 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo
Number of subjects: 868
Study 15282351 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (HCV genotype 1)
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo (HCV genotype 1)
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin (HCV genotype 1)
Number of subjects: 868
Study 15282351 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin (HCV genotype 2 or 3)
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo (HCV genotype 2 or 3)
Number of subjects: 868
Study 15282351 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2a plus ribavirin (HCV genotype 2 or 3)
Number of subjects: 868
Study 15282351 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a
Number of subjects: 868
Study 15282351 — intervention group
Group type: EXPERIMENTAL
Intervention: ribavirin
Number of subjects: 868
Study 12584575 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 12
Study 12584575 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study 9690944 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of erythropoietin (Epoetin beta)
Number of subjects: 0
Study 8080985 — intervention group
Group type: EXPERIMENTAL
Intervention: RGD peptide matrix treatment
Number of subjects: 0
Study 8080985 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 8080985 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus RGD peptide matrix
Number of subjects: 0
Study 8080985 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy plus placebo
Number of subjects: 0
Study 2753986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, single oral dose)
Number of subjects: 18
Study 2753986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, 3 times daily, chronic treatment for 4-12 weeks)
Number of subjects: 18
Study 2753986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (2 mg, 3 times daily, chronic treatment for 4-104 weeks)
Number of subjects: 18
Study 2753986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 360247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (CDZ)
Number of subjects: 447
Study 360247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 447
Study 29203842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 15 mg/day
Number of subjects: 101
Study 29203842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine 30 mg/day
Number of subjects: 101
Study 29203842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 27325857 — intervention group
Group type: COMPARATOR
Intervention: Rd continuous
Number of subjects: 1623
Study 27325857 — intervention group
Group type: COMPARATOR
Intervention: Rd18
Number of subjects: 1623
Study 23543311 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a alone (group A)
Number of subjects: 153
Study 23543311 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFNα‐2a/RBV (group B)
Number of subjects: 153
Study 23543311 — intervention group
Group type: COMPARATOR
Intervention: Weekly PEG‐IFNα‐2a (group C)
Number of subjects: 153
Study 23543311 — intervention group
Group type: COMPARATOR
Intervention: Biweekly therapy (group D)
Number of subjects: 153
Study 23543311 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFNα‐2a/RBV (group E)
Number of subjects: 153
Study 23543311 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFNα‐2a/RBV/fluvastatin (group F)
Number of subjects: 153
Study 24237718 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental training programme
Number of subjects: 142
Study 24237718 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study 20804630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry powder (1500 mg per day for 6 months)
Number of subjects: 42
Study 20804630 — intervention group
Group type: COMPARATOR
Intervention: Control (no cranberry treatment)
Number of subjects: 42
Study 18001723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 33
Study 18001723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 16613274 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture-anesthesia device (EAAD) used for localizing brachiplex nerve blocking
Number of subjects: 120
Study 16613274 — intervention group
Group type: COMPARATOR
Intervention: Paresthesia elicitation used for localizing brachiplex nerve blocking (Control)
Number of subjects: 120
Study 14983613 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid clinic model intervention including diet, medication, and follow-up by nurses and physicians.
Number of subjects: 0
Study 14983613 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control group treatment by general internists.
Number of subjects: 0
Study 10925523 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy emmetropic or ametropic eyes
Number of subjects: 291
Study 10925523 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 291
Study 10925523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with ocular hypertension
Number of subjects: 291
Study 8826204 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior training group (N=67)
Number of subjects: 106
Study 8826204 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=39)
Number of subjects: 106
Study 1314147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (5000 IU subcutaneously once daily for six days)
Number of subjects: 82
Study 1314147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2982534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sodium bicarbonate
Number of subjects: 0
Study 2982534 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of ammonium chloride
Number of subjects: 0
Study 30368584 — intervention group
Group type: EXPERIMENTAL
Intervention: H3B-6527 (200 mg dose) after a high-fat meal
Number of subjects: 12
Study 30368584 — intervention group
Group type: COMPARATOR
Intervention: H3B-6527 (200 mg dose) after fasting
Number of subjects: 12
Study 29901710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Pattern with 500 g lean, unprocessed red meat (Med-Red)
Number of subjects: 41
Study 29901710 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Pattern with 200 g lean, unprocessed red meat (Med-Control)
Number of subjects: 41
Study 29901710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Med-Red and Med-Control
Number of subjects: 41
Study 27036221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 300
Study 27036221 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 300
Study 23971520 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR (Start. Transform. Achieve. Results.) intervention
Number of subjects: 1145
Study 22179735 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg weekly
Number of subjects: 1000
Study 22179735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 3 g daily
Number of subjects: 1000
Study 22179735 — intervention group
Group type: COMPARATOR
Intervention: EASi-QoL
Number of subjects: 1000
Study 22179735 — intervention group
Group type: COMPARATOR
Intervention: ASQoL
Number of subjects: 1000
Study 20223454 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg of mifepristone every 30 days for 3 months
Number of subjects: 36
Study 20223454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 36
Study 18807577 — intervention group
Group type: EXPERIMENTAL
Intervention: D-003 5 mg/d
Number of subjects: 56
Study 18807577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15622150 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (not specified)
Number of subjects: 21
Study 15622150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 21
Study 15622150 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 21
Study 11936486 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokarin
Number of subjects: 29
Study 11936486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (5000 cGy, Cisplatin 75 mg/m2, Fluorouracil 1000 mg/m2 for 4 days)
Number of subjects: 119
Study 8789470 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal anastomoses of vein grafts sutured after aortic declamping during partial occlusion of the aorta (Group A)
Number of subjects: 60
Study 8789470 — intervention group
Group type: COMPARATOR
Intervention: Proximal anastomoses done during aortic cross‐clamping (Group B)
Number of subjects: 60
Study 8789470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 8789470 — intervention group
Group type: COMPARATOR
Intervention: Aortic cross‐clamping (Group B)
Number of subjects: 60
Study 3225664 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine activity monitoring
Number of subjects: 67
Study 3225664 — intervention group
Group type: COMPARATOR
Intervention: Palpation for contractions
Number of subjects: 67
Study 29471068 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie diet (LCD)
Number of subjects: 123
Study 28760210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour high-sensitivity troponin T (hs-TnT) protocol
Number of subjects: 5400
Study 28760210 — intervention group
Group type: COMPARATOR
Intervention: Usual care of standard troponin reporting evaluated at 3 and 6 hours
Number of subjects: 5400
Study 25623276 — intervention group
Group type: EXPERIMENTAL
Intervention: perioperative nutrition
Number of subjects: 280
Study 25623276 — intervention group
Group type: COMPARATOR
Intervention: no nutrition
Number of subjects: 280
Study 24108526 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (continuous infusion titrated to maintain heart rate between 80/min and 94/min)
Number of subjects: 154
Study 24108526 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 154
Study 21079437 — intervention group
Group type: EXPERIMENTAL
Intervention: Catcher's mask
Number of subjects: 0
Study 21079437 — intervention group
Group type: COMPARATOR
Intervention: No mask
Number of subjects: 0
Study 18414904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortex port
Number of subjects: 200
Study 18414904 — intervention group
Group type: COMPARATOR
Intervention: Celsite port
Number of subjects: 200
Study 21106625 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (n=169)
Number of subjects: 340
Study 21106625 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP (n=171)
Number of subjects: 340
Study 15668416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal levodopa/carbidopa infusion
Number of subjects: 24
Study 15668416 — intervention group
Group type: COMPARATOR
Intervention: Conventional combination therapies
Number of subjects: 24
Study 12036647 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ropivacaine 1%
Number of subjects: 64
Study 12036647 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine 4%
Number of subjects: 64
Study 9782681 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylactic chemotherapy
Number of subjects: 47
Study 7945600 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in a quiet environment (high setting: 76 mm Hg, low setting: 138 mm Hg)
Number of subjects: 49
Study 7945600 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements in a moving ambulance (high setting: 76 mm Hg, low setting: 138 mm Hg)
Number of subjects: 49
Study 7945600 — intervention group
Group type: COMPARATOR
Intervention: Comparison of quiet environment vs moving ambulance measurements
Number of subjects: 49
Study 2905187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin (7500 anti-Xa units, once daily)
Number of subjects: 1896